{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:47:34Z","timestamp":1794887254728,"version":"4.9.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":103,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004354","name":"Svensk K\u00e4rnbr\u00e4nslehantering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004354","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004599","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100931","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T02:49:08Z","timestamp":1744685348000},"page":"100931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-1543","authenticated-orcid":false,"given":"Anke","family":"Richters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt","family":"Suelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Franken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Rikhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Westgeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Aben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Robbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus","family":"Kiemeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toine","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Delaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilze","family":"van Onna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Wijsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kerkhofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Leliveld-Kors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja Goossens-","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd-Jan","family":"Molijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Roelofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Duizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.100931_bib0001","first-page":"33","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","author":"Powles","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2025.100931_bib0002","unstructured":"Witjes J.A., Bruins H.M., Carrion Albert, Cathomas Richard, Comp\u00e9rat Eva, Efstathiou Jason A, Fietkau Rainer, Gakis Georgios, Lorch Anja, Martini Alberto, Mertens Laura S., Meijer Richard P, Milowsky Matthew I., Neuzillet Yann, Panebianco Valeria, Redlef John, Rink Michael, Rouanne Mathieu, Thalmann George N, S\u00e6bj\u00f8rnsen S\u00e6bj\u00f8rn, Veskim\u00e4e Erik, A.G. VdH. (2023) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines European urology."},{"key":"10.1016\/j.ctarc.2025.100931_bib0003","series-title":"Pembrolizumab As Second-Line Therapy For Advanced Urothelial Carcinoma","first-page":"376","author":"Bellmunt","year":"2017"},{"key":"10.1016\/j.ctarc.2025.100931_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.32697","article-title":"Assessing the efficacy-effectiveness gap for cancer therapies: a comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics","volume":"126","author":"Phillips","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2025.100931_bib0005","first-page":"130","article-title":"Efficacy-effectiveness gaps in oncology: looking beyond survival","author":"Wilson","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2025.100931_bib0006","unstructured":"The Netherlands Comprehensive Cancer Organisation (IKNL). (2023) Netherlands cancer registry data ed.)."},{"key":"10.1016\/j.ctarc.2025.100931_bib0007","article-title":"Treatment patterns and use of immune checkpoint inhibitors among patients with metastatic bladder cancer in a Dutch nationwide population-based cohort","author":"Anke","year":"2023","journal-title":"Europ. Urol. Open Sci."},{"key":"10.1016\/j.ctarc.2025.100931_bib0008","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of>2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2025.100931_bib0009","first-page":"34","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","author":"Balar","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2025.100931_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047256","article-title":"Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the \u2018trials within cohorts\u2019 study ProBCI","volume":"11","author":"Richters","year":"2021","journal-title":"BMJ Open."},{"key":"10.1016\/j.ctarc.2025.100931_bib0011","first-page":"12","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","author":"Guyot","year":"2012","journal-title":"BMC. Med. Res. Methodol."},{"key":"10.1016\/j.ctarc.2025.100931_bib0012","first-page":"390","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","author":"Powles","year":"2024","journal-title":"New England J. Med."},{"key":"10.1016\/j.ctarc.2025.100931_bib0013","first-page":"389","article-title":"Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma","author":"Van Der Heijden","year":"2023","journal-title":"New England J. Med."},{"key":"10.1016\/j.ctarc.2025.100931_bib0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Re: thomas Powles, Bego\u00f1a P\u00e9rez-Valderrama, Shilpa Gupta, et al. enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Grande","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100931_bib0016","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03682-w","article-title":"Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study","volume":"73","author":"Massari","year":"2024","journal-title":"Cancer Immunol., Immunother."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:57:58Z","timestamp":1762628278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225000656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":15,"alternative-id":["S2468294225000656"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100931","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100931"}}